One week after the effectiveness of Pfizer’s vaccine was announced, Modern pharmaceutical company unveiled the characteristics of its new coronavirus vaccine. In a statement, the company gave more hope to overcome this pandemic that has changed our lives since last March. In this essay a total of 30,000 people have participated, in collaboration with the United States National Institutes of Health.
Despite hundreds of studies and projects to find a cure for the coronavirus, These two vaccines have taken the lead. They will be, possibly, those that first arrive at the beginning of next year 2021 and, although they share the same final objective – to end the coronavirus- there are many characteristics that clearly differentiate them.
Effectiveness and participation in tests
The most important and decisive for the next few months and the first vaccinations. Pfizer reported last Monday that its vaccine was 90% effective (tested on more than 43,000 people). Seven days later and starting a new week, the American pharmaceutical company Moderna announces that its vaccine against the coronavirus, BNT162b2, has an efficacy of 94.5%. Even experts warn that Moderna’s vaccine doses are three times higher than Pfizer’s. It is also distributed in two doses, with a difference of 28 days between each one.
Moderna’s vaccine has had the collaboration of 30,000 people. Of them, one half were injected with the vaccine, while the other half received a dose of salt water as a placebo. The conclusions of this analysis left 95 symptomatic infections. 90 of these collaborators in the study belong to the group that received the placebo and not the true treatment. Among its participants, Moderna includes 7,000 people over 65 and 5,000 under it, but with chronic diseases associated with a higher risk.
It was one of the most outstanding characteristics of Fernando Simón a week ago. The epidemiologist was optimistic about the arrival of the Pfizer vaccine, but its distribution seemed to be a small problem for the vaccination campaign. For its characteristics, This vaccine required to be kept at temperatures as freezing as -70º until the moment of its injection. A situation that would determine a problem when it comes to its distribution as there are no containers that keep that temperature when it is transported.
At this point, the Modern vaccine wins, that it would be much easier to keep and distribute to the different countries to start vaccinating the population. In the same statement, the pharmaceutical company reports that its ‘mRNA-1273’ vaccine can be kept “between 2 ° and 8 °, the temperature of a standard household refrigerator, for 30 days.” They even claim that it can be stored at -20ºC for a period of up to six months and at room temperature for 12 hours.
Deadlines and distribution
The first vaccination campaigns are planned for early 2021, like the Pfizer vaccine, although the company will request “in the coming weeks” that its use be authorized for emergencies. But nevertheless, The American pharmaceutical company has in mind to produce 20 million of Moderna’s vaccine to begin distributing them in the United States before the end of the year. In addition, the company is already working on two channels, one to supply the country itself and the other to be distributed throughout Europe, at the hands of Rovi laboratories in Madrid.
Looking ahead to 2021, Moderna’s vaccine is expected to reach between 500 and 1 billion doses worldwide. Their arrival in Europe will take a little longer, although the company hopes that an agreement will be reached with the authorities to start distributing them early next year.
Pfizer’s vaccine expects to produce about 50 million doses before the end of 2020, reaching 1.3 billion vaccines next year. Spain has already reached an agreement whereby it will receive 20 million doses to vaccinate about 10 million people in the first months of 2021. Both vaccines require two doses to be effective.